24 July 2022

MEMORANDUM FOR: KARINE JEAN-PIERRE
ASSISTANT TO THE PRESIDENT AND
WHITE HOUSE PRESS SECRETARY

FROM: KEVIN C. O’CONNOR, D.O., FAAFP
PHYSICIAN TO THE PRESIDENT

SUBJECT: President Biden SARS-CoV-2 Update

President Biden completed his third full day of PAXLOVID last night. His symptoms continue to improve significantly. His predominant symptom now is sore throat. This is most likely a result of lymphoid activation as his body clears the virus, and is thus encouraging. His rhinorrhea, cough and body aches have diminished considerably. His voice remains a bit deep. His pulse, blood pressure, respiratory rate and temperature all remain normal. His oxygen saturation continues to be excellent on room air. His lungs remain clear.

The President continues to tolerate treatment well. We will continue PAXLOVID as planned. His symptoms will continue to be treated supportively with oral hydration, acetaminophen (TYLENOL), and the albuterol inhaler that he uses as needed for occasional cough. He is experiencing no shortness of breath at all. He will continue low dose aspirin as an alternative type of blood thinner.

The President is responding to therapy as expected. As I’ve stated previously, the BA5 variant is particularly transmissible and he will continue to isolate in accordance with Centers for Disease Control and Prevention (CDC) recommendations. We will continue to monitor him closely, during this very common outpatient treatment regimen.

As promised, I will keep your office updated with any changes in his condition or treatment plan.

Respectfully submitted,

Kevin C. O’Connor, D.O., FAAFP
Physician to the President
The White House

Associate Professor, The George Washington University School of Medicine & Health Sciences